CN112770745B - 用于治疗特定白血病的化合物 - Google Patents
用于治疗特定白血病的化合物 Download PDFInfo
- Publication number
- CN112770745B CN112770745B CN201980060896.3A CN201980060896A CN112770745B CN 112770745 B CN112770745 B CN 112770745B CN 201980060896 A CN201980060896 A CN 201980060896A CN 112770745 B CN112770745 B CN 112770745B
- Authority
- CN
- China
- Prior art keywords
- substituted
- alkyl
- group
- cycloalkyl
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/16—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210969394.6A CN115448908B (zh) | 2018-09-18 | 2019-09-17 | 用于治疗特定白血病的化合物 |
| CN202210968772.9A CN115215838B (zh) | 2018-09-18 | 2019-09-17 | 用于治疗特定白血病的化合物 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862733029P | 2018-09-18 | 2018-09-18 | |
| US62/733,029 | 2018-09-18 | ||
| US201962816637P | 2019-03-11 | 2019-03-11 | |
| US62/816,637 | 2019-03-11 | ||
| US201962889929P | 2019-08-21 | 2019-08-21 | |
| US62/889,929 | 2019-08-21 | ||
| PCT/US2019/051567 WO2020061086A2 (en) | 2018-09-18 | 2019-09-17 | Compounds for treating certain leukemias |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210969394.6A Division CN115448908B (zh) | 2018-09-18 | 2019-09-17 | 用于治疗特定白血病的化合物 |
| CN202210968772.9A Division CN115215838B (zh) | 2018-09-18 | 2019-09-17 | 用于治疗特定白血病的化合物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN112770745A CN112770745A (zh) | 2021-05-07 |
| CN112770745B true CN112770745B (zh) | 2022-09-02 |
Family
ID=69774840
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201980060896.3A Active CN112770745B (zh) | 2018-09-18 | 2019-09-17 | 用于治疗特定白血病的化合物 |
| CN202210968772.9A Active CN115215838B (zh) | 2018-09-18 | 2019-09-17 | 用于治疗特定白血病的化合物 |
| CN202210969394.6A Active CN115448908B (zh) | 2018-09-18 | 2019-09-17 | 用于治疗特定白血病的化合物 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210968772.9A Active CN115215838B (zh) | 2018-09-18 | 2019-09-17 | 用于治疗特定白血病的化合物 |
| CN202210969394.6A Active CN115448908B (zh) | 2018-09-18 | 2019-09-17 | 用于治疗特定白血病的化合物 |
Country Status (19)
| Country | Link |
|---|---|
| US (4) | US10889571B2 (https=) |
| EP (1) | EP3852745A4 (https=) |
| JP (2) | JP7611832B2 (https=) |
| KR (2) | KR20210061377A (https=) |
| CN (3) | CN112770745B (https=) |
| AU (2) | AU2019342102C1 (https=) |
| BR (1) | BR112021004051A2 (https=) |
| CA (1) | CA3110576A1 (https=) |
| CL (1) | CL2021000637A1 (https=) |
| CO (1) | CO2021004704A2 (https=) |
| IL (2) | IL281427B2 (https=) |
| MA (1) | MA53664A (https=) |
| MX (2) | MX2021003093A (https=) |
| NZ (1) | NZ773110A (https=) |
| PE (2) | PE20252740A1 (https=) |
| SG (1) | SG11202102367TA (https=) |
| TW (1) | TWI826525B (https=) |
| WO (1) | WO2020061086A2 (https=) |
| ZA (1) | ZA202101304B (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL281427B2 (en) | 2018-09-18 | 2026-01-01 | Terns Inc | Compounds that inhibit tyrosine kinase activity for use in the treatment of leukemia |
| JP7640458B2 (ja) | 2018-10-05 | 2025-03-05 | アンナプルナ バイオ インコーポレイテッド | Ａｐｊ受容体活性に関連する状態を処置するための化合物および組成物 |
| CN111320609A (zh) | 2018-12-13 | 2020-06-23 | 拓臻股份有限公司 | 一种THRβ受体激动剂化合物及其制备方法和用途 |
| US11149009B2 (en) | 2019-03-11 | 2021-10-19 | Inflarx Gmbh | Fused piperidinyl bicyclic and related compounds as modulators of C5A receptor |
| WO2021018194A1 (en) * | 2019-07-29 | 2021-02-04 | Ascentage Pharma (Suzhou) Co., Ltd. | Heterocyclic compounds as bcr-abl inhibitors |
| AU2020336272A1 (en) | 2019-08-23 | 2022-04-14 | Terns Pharmaceuticals, Inc. | Thyroid hormone receptor beta agonist compounds |
| CN114375193B (zh) | 2019-09-12 | 2024-05-14 | 拓臻制药公司 | 甲状腺激素受体β激动剂化合物 |
| CA3212130A1 (en) * | 2021-03-03 | 2022-09-09 | Terns Pharmaceuticals, Inc. | Thyroid hormone receptor beta agonist compounds |
| CN116375650B (zh) * | 2022-12-30 | 2025-08-05 | 浙江美诺华药物化学有限公司 | 一种替戈拉生中间体的制备方法 |
| US20240398794A1 (en) | 2023-04-07 | 2024-12-05 | Terns Pharmaceuticals, Inc. | COMBINATIONS OF GLP-1R AND THRß AGONISTS AND METHODS OF USE THEREOF |
| TW202525293A (zh) * | 2023-08-31 | 2025-07-01 | 美商拓臻製藥公司 | 用於治療癌症之組合 |
| WO2025226724A1 (en) * | 2024-04-23 | 2025-10-30 | Terns Pharmaceuticals, Inc. | Bcr-abl1 inhibitors for use in treating cancer |
| CN120842151A (zh) * | 2024-04-26 | 2025-10-28 | 北京英飞智药科技有限公司 | 一种2-芳基苯并咪唑类化合物及其制备方法与应用 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018191146A1 (en) * | 2017-04-10 | 2018-10-18 | Navitor Pharmaceuticals, Inc. | Heteroaryl rheb inhibitors and uses thereof |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2236220C2 (ru) | 1998-05-22 | 2004-09-20 | Аванир Фармасьютикэлз | Аналоги бензимидазола в качестве понижающих регуляторов ige |
| SE0003476D0 (sv) | 2000-09-28 | 2000-09-28 | Astrazeneca Ab | Compounds |
| TW200304820A (en) * | 2002-03-25 | 2003-10-16 | Avanir Pharmaceuticals | Use of benzimidazole analogs in the treatment of cell proliferation |
| PE20061378A1 (es) * | 2005-04-20 | 2006-12-03 | Smithkline Beecham Corp | INHIBIDORES DE LA ACTIVIDAD DE Akt |
| AR063311A1 (es) * | 2006-10-18 | 2009-01-21 | Novartis Ag | Compuestos organicos |
| CN101553468A (zh) * | 2006-10-18 | 2009-10-07 | 诺瓦提斯公司 | 有机化合物 |
| GB0800035D0 (en) | 2008-01-02 | 2008-02-13 | Glaxo Group Ltd | Compounds |
| WO2013033093A1 (en) | 2011-08-29 | 2013-03-07 | Biocryst Pharmaceuticals, Inc. | Heterocyclic compounds as janus kinase inhibitors |
| KR20150008406A (ko) | 2012-05-15 | 2015-01-22 | 노파르티스 아게 | Abl1, abl2 및 bcr-abl1의 활성을 억제하기 위한 벤즈아미드 유도체 |
| PT2861579T (pt) | 2012-05-15 | 2018-04-27 | Novartis Ag | Derivados de benzamida para inibir a atividade de abl1, abl2 e bcr-abl |
| WO2013171641A1 (en) | 2012-05-15 | 2013-11-21 | Novartis Ag | Compounds and compositions for inhibiting the activity of abl1, abl2 and bcr-abl1 |
| US9550737B2 (en) | 2012-06-11 | 2017-01-24 | Ucb Biopharma Sprl | TNF -α modulating benzimidazoles |
| CN103113355B (zh) | 2013-02-27 | 2014-08-13 | 无锡爱内特生物科技有限公司 | 一种Bcr/Abl酪氨酸激酶抑制剂及其制备方法和在治疗慢性粒细胞白血病中的应用 |
| GB201401086D0 (en) | 2014-01-23 | 2014-03-12 | Galapagos Nv | Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders |
| US9931342B2 (en) | 2016-02-02 | 2018-04-03 | Duke University | Compositions and methods for the treatment of cancer |
| JP2019515932A (ja) | 2016-04-29 | 2019-06-13 | アスター バイオテック リミテッド ライアビリティ カンパニー | チロシンキナーゼｂｃｒ−ａｂｌ阻害剤としての新規複素環化合物 |
| US11091462B2 (en) | 2017-01-20 | 2021-08-17 | Shenzhen Targetrx, Inc. | (Hetero)arylamide compound for inhibiting protein kinase activity |
| US10875853B2 (en) | 2017-01-20 | 2020-12-29 | Shenzhen Targetrx, Inc. | (Hetero)arylamide compound for inhibiting protein kinase activity |
| WO2019173761A1 (en) | 2018-03-09 | 2019-09-12 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | C-abl tyrosine kinase inhibitory compound embodiments and methods of making and using the same |
| IL281427B2 (en) | 2018-09-18 | 2026-01-01 | Terns Inc | Compounds that inhibit tyrosine kinase activity for use in the treatment of leukemia |
| US20240262842A1 (en) | 2021-04-27 | 2024-08-08 | Merck Sharp & Dohme Llc | Small molecule inhibitors of kras g12c mutant |
| WO2023051681A1 (zh) | 2021-09-30 | 2023-04-06 | 江苏豪森药业集团有限公司 | 四元稠环类化合物及其制备方法和应用 |
| KR20260004344A (ko) | 2023-03-30 | 2026-01-08 | 장쑤 한서 파마슈티칼 그룹 캄파니 리미티드 | 4차 융합 고리 화합물의 염 결정 형태, 및 이의 제조 방법 및 이의 용도 |
| TW202525293A (zh) | 2023-08-31 | 2025-07-01 | 美商拓臻製藥公司 | 用於治療癌症之組合 |
-
2019
- 2019-09-17 IL IL281427A patent/IL281427B2/en unknown
- 2019-09-17 MA MA053664A patent/MA53664A/fr unknown
- 2019-09-17 SG SG11202102367TA patent/SG11202102367TA/en unknown
- 2019-09-17 EP EP19862388.6A patent/EP3852745A4/en active Pending
- 2019-09-17 KR KR1020217011001A patent/KR20210061377A/ko active Pending
- 2019-09-17 BR BR112021004051-0A patent/BR112021004051A2/pt unknown
- 2019-09-17 PE PE2025001942A patent/PE20252740A1/es unknown
- 2019-09-17 MX MX2021003093A patent/MX2021003093A/es unknown
- 2019-09-17 CA CA3110576A patent/CA3110576A1/en active Pending
- 2019-09-17 IL IL322515A patent/IL322515A/en unknown
- 2019-09-17 PE PE2021000343A patent/PE20211644A1/es unknown
- 2019-09-17 KR KR1020267002852A patent/KR20260019669A/ko active Pending
- 2019-09-17 CN CN201980060896.3A patent/CN112770745B/zh active Active
- 2019-09-17 NZ NZ773110A patent/NZ773110A/en unknown
- 2019-09-17 CN CN202210968772.9A patent/CN115215838B/zh active Active
- 2019-09-17 AU AU2019342102A patent/AU2019342102C1/en active Active
- 2019-09-17 US US16/573,860 patent/US10889571B2/en active Active
- 2019-09-17 JP JP2021539486A patent/JP7611832B2/ja active Active
- 2019-09-17 CN CN202210969394.6A patent/CN115448908B/zh active Active
- 2019-09-17 TW TW108133432A patent/TWI826525B/zh active
- 2019-09-17 WO PCT/US2019/051567 patent/WO2020061086A2/en not_active Ceased
-
2021
- 2021-02-25 ZA ZA2021/01304A patent/ZA202101304B/en unknown
- 2021-03-16 CL CL2021000637A patent/CL2021000637A1/es unknown
- 2021-03-16 MX MX2023007714A patent/MX2023007714A/es unknown
- 2021-04-15 CO CONC2021/0004704A patent/CO2021004704A2/es unknown
-
2023
- 2023-06-22 US US18/339,516 patent/US12240835B2/en active Active
-
2024
- 2024-12-20 AU AU2024287115A patent/AU2024287115A1/en active Pending
- 2024-12-24 JP JP2024227127A patent/JP2025066704A/ja active Pending
-
2025
- 2025-01-30 US US19/041,557 patent/US20250276961A1/en active Pending
- 2025-03-06 US US19/072,824 patent/US12454524B2/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018191146A1 (en) * | 2017-04-10 | 2018-10-18 | Navitor Pharmaceuticals, Inc. | Heteroaryl rheb inhibitors and uses thereof |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN112770745B (zh) | 用于治疗特定白血病的化合物 | |
| CN111217797B (zh) | Rho相关蛋白激酶抑制剂、包含其的药物组合物及其制备方法和用途 | |
| WO2023045960A1 (zh) | 一种吡啶类衍生物及其用途 | |
| EP3894416B1 (en) | Ferroportin inhibitors and methods of use | |
| CN102356081B (zh) | 减少β-淀粉状蛋白生成的双环化合物 | |
| CN114430743A (zh) | 甲状腺激素受体β激动剂化合物 | |
| TW201630899A (zh) | 作為ｒｏｃｋ抑制劑的環狀脲類 | |
| CN115427035B (zh) | Enl/af9 yeats抑制剂 | |
| CN108473497A (zh) | Ep4拮抗剂 | |
| HK40052099A (en) | Compounds for treating certain leukemias | |
| HK40052099B (en) | Compounds for treating certain leukemias | |
| TW202012414A (zh) | 三環ask1抑制劑 | |
| RU2804709C9 (ru) | Соединения для лечения некоторых лейкозов | |
| JP7677995B2 (ja) | ガレクチン－３の低分子阻害剤 | |
| RU2804709C2 (ru) | Соединения для лечения некоторых лейкозов | |
| BR122025027049A2 (pt) | Compostos, sal de adição de ácido farmaceuticamente aceitável, seu método de produção e métodos de síntese de compostos | |
| HK40077347B (zh) | Raf激酶的抑制剂 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40052099 Country of ref document: HK |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant |